MarÃa AsunciÃ³n Esteve-Pastor

List of Publications by Year
in descending order

60 papers	1,087 citations	430754 18 h-index	434063 31 g-index
62 all docs	62 docs citations	62 times ranked	1588 citing authors

#	Article	IF	Citations
1	Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors. Diabetes Research and Clinical Practice, 2022, 184, 109215.	1.1	0
2	Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry. Frontiers in Cardiovascular Medicine, 2022, 9, 856222.	1.1	4
3	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. Thrombosis and Haemostasis, 2021, 121, 1107-1114.	1.8	4
4	Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. European Journal of Clinical Investigation, 2021, 51, e13431.	1.7	3
5	Comparison of Aortic Gradient and Ventricular Mass after Valve Replacement for Aortic Stenosis with Rapid Deployment, Sutureless, and Conventional Bioprostheses. Cardiology, 2021, 146, 656-666.	0.6	2
6	Impact of frailty and atrial fibrillation in elderly patients with acute coronary syndromes. European Journal of Clinical Investigation, 2021, 51, e13505.	1.7	3
7	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	1.8	7
8	Relationship between multimorbidity and outcomes in atrial fibrillation. Experimental Gerontology, 2021, 153, 111482.	1.2	16
9	One‐year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry. British Journal of Clinical Pharmacology, 2020, 86, 1052-1061.	1.1	7
10	Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry. Journal of the American Heart Association, 2020, 9, e013789.	1.6	19
11	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. Expert Opinion on Pharmacotherapy, 2020, 21, 1867-1881.	0.9	3
12	A nurse‐led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. International Journal of Clinical Practice, 2020, 74, e13634.	0.8	13
13	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIIA Registry. Annals of Medicine, 2020, 52, 300-309.	1.5	7
14	Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world"Nationwide Registry: Insights From the FANTASIIA Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 316-323.	1.0	1
15	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed), 2020, 73, 749-757.	0.4	38
16	Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study. European Journal of Internal Medicine, 2020, 78, 63-68.	1.0	3
17	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. Thrombosis and Haemostasis, 2019, 119, 1901-1919.	1.8	57
18	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke, 2019, 50, 1372-1379.	1.0	48

#	Article	IF	Citations
19	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open, 2019, 9, e033712.	0.8	3
20	Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?. Thrombosis and Haemostasis, 2019, 119, 1891-1893.	1.8	5
21	Chronic Kidney Disease and Thirdâ€Generation P2Y$_{12}$ Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year. Journal of Clinical Pharmacology, 2019, 59, 295-302.	1.0	2
22	Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. European Journal of Internal Medicine, 2019, 61, 48-53.	1.0	19
23	Riesgo embÃ³lico, riesgo isquÃ©mico y riesgo hemorrÃ¡gico. Revista Espanola De Cardiologia Suplementos, 2019, 18, 3-8.	0.2	0
24	Risk factors for the development of incident atrial fibrillation in patients with cardiac implantable electronic devices. European Journal of Internal Medicine, 2018, 52, 54-59.	1.0	8
25	Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroftâ€Gault, Modification of Diet in Renal Diseaseâ€4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7, .	1.6	16
26	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12929.	1.7	5
27	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. International Journal of Clinical Practice, 2018, 72, e13069.	0.8	4
28	Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from <scp>FANTASIIA</scp> Registry. European Journal of Clinical Investigation, 2018, 48, e12910.	1.7	5
29	Quality of oral anticoagulation with vitamin K antagonists in â€˜real-worldâ€™ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace, 2018, 20, 1435-1441.	0.7	39
30	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry. Thrombosis and Haemostasis, 2018, 118, 279-287.	1.8	17
31	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clinical Therapeutics, 2018, 40, 114-122.	1.1	21
32	Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace, 2018, 20, 1577-1583.	0.7	93
33	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the â€œReal-Worldâ€•vs Clinical Trials. Mayo Clinic Proceedings, 2018, 93, 1065-1073.	1.4	28
34	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. Journal of General Internal Medicine, 2018, 33, 847-854.	1.3	14
35	Enhancing the â€˜real worldâ€™ prediction of cardiovascular events and major bleeding with the CHA$_2$DS$_2$-VASc and HAS-BLED scores using multiple biomarkers. Annals of Medicine, 2018, 50, 26-34.	1.5	22
36	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in â€˜real-worldâ€™ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology, 2018, 254, 125-131.	0.8	18

#	Article	IF	Citations
37	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA 2 DS 2 -VASc and HAS-BLED. American Heart Journal, 2018, 197, 27-34.	1.2	8
38	Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 57-65.	1.0	21
39	Differences of Matrix Metalloproteinase 2 Expression between Left and Right Ventricles in Response to Nandrolone Decanoate and/or Swimming Training in Mice. Chinese Medical Journal, 2018, 131, 207-212.	0.9	2
40	Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines. PLoS ONE, 2018, 13, e0208069.	1.1	4
41	Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores. Journal of the American Heart Association, 2018, 7, e009766.	1.6	23
42	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circulation Journal, 2018, 82, 1286-1292.	0.7	4
43	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World"in Patients With Atrial Fibrillation. American Journal of Cardiology, 2018, 122, 785-792.	0.7	12
44	Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. Cardiology Journal, 2018, 25, 151-154.	0.5	4
45	Evaluación de los esquemas de riesgo hemorrágico HAS-BLED y ORBIT en pacientes con fibrilación auricular no valvular tratados con anticoagulación oral. Revista Espanola De Cardiologia, 2017, 70, 132-133.	0.6	0
46	Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. European Journal of Cardiovascular Nursing, 2017, 16, 696-703.	0.4	10
47	Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. Revista Espanola De Cardiologia (English Ed), 2017, 70, 132-133.	0.4	0
48	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2176-2181.	0.7	19
49	Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. American Journal of Hypertension, 2017, 30, 1063-1065.	1.0	13
50	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066.	1.6	16
51	Long‐Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC‐Stroke and CHA$_2$DS$_2$‐VASc Scores. Journal of the American Heart Association, 2017, 6, .	1.6	42
52	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety, 2017, 16, 1051-1062.	1.0	24
53	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thrombosis and Haemostasis, 2017, 117, 1448-1454.	1.8	74
54	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. Thrombosis and Haemostasis, 2017, 117, 2261-2266.	1.8	51

#	Article	IF	Citations
55	Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. Thrombosis and Haemostasis, 2017, 117, 1848-1858.	1.8	56
56	Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. Oncotarget, 2017, 8, 80182-80191.	0.8	12
57	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. Molecules, 2016, 21, 284.	1.7	2
58	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. Circulation Journal, 2016, 80, 2102-2108.	0.7	21
59	The SAMe-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 177-187.	0.6	18
60	The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines. Thrombosis and Haemostasis, 2015, 114, 872-874.	1.8	0